pembrolizumab
-
Still to open Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I) Brief Summary Background: SARS-CoV-2 is the virus that causes COVID-19.Some people who recover from an acute COVID-19 infection may continue to have symptoms that persist for...- forestglip
- Thread
- avindra nath long covid neurological symptoms pembrolizumab
- Replies: 3
- Forum: Recruitment into current ME/CFS research studies
-
mRNA skin cancer vaccine shows protection at 5-year follow-up, Moderna and Merck say
Full article at Arstechnica- hotblack
- Thread
- intismeran mrna pembrolizumab
- Replies: 1
- Forum: Other health news and research